Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β₂-agonist fixed-dose combination: RE²SPOND rationale and study design

Stephen I Rennard,1,2 Fernando J Martinez,3,4 Klaus F Rabe,5–7 Sanjay Sethi,8 Emilio Pizzichini,9 Andrew McVor,10 Shahid Siddiqui,11 Antonio Anzueto,12 Haiyuan Zhu13

1Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA; 2AstraZeneca, Cambridge, UK; 3Joan and Sanford I Weill Department of Medicine, Weill Cornell University, New York, NY, USA; 4Department of Internal Medicine, Michigan Health System, Ann Arbor, MI, USA; 5LungenClinic Grosshansdorf, Grosshansdorf, Germany; 6Department of Medicine, University of Buffalo, State University of New York, Buffalo, NY, USA; 7Department of Medicine, Universidade Federal de Santa Catarina, Santa Catarina, Brazil; 8Firestone Institute of Respiratory Health, St Joseph’s Healthcare, McMaster University, Hamilton, ON, Canada; 9AstraZeneca, Gaithersburg, MD; 10South Texas Veterans Health Care System at San Antonio, San Antonio, TX; 11Allergan plc, Jersey City, NJ, USA

Correspondence: Stephen I Rennard
985910 University of Nebraska Medical Center, Omaha, NE 68198, USA
Tel +1 402 559 7313
Fax +1 402 559 4878
Email stephen.rennard@astrazeneca.com

Background: Roflumilast, a once-daily, selective phosphodiesterase-4 inhibitor, reduces the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. The RE²SPOND study is examining whether roflumilast, when added to an inhaled corticosteroid/long-acting β₂-agonist (ICS/LABA) fixed-dose combination (FDC), further reduces exacerbations. The methodology is described herein.

Methods: In this Phase IV, multicenter, double-blind, placebo-controlled, parallel-group trial, participants were randomized 1:1 (stratified by long-acting muscarinic antagonist use) to receive roflumilast or placebo, plus ICS/LABA FDC, for 52 weeks. Eligible participants had severe COPD associated with chronic bronchitis, had two or more moderate–severe exacerbations within 12 months, and were receiving ICS/LABA FDC for ≥3 months. The primary efficacy measure is the rate of moderate or severe COPD exacerbations per participant per year. The secondary efficacy outcomes include mean change in prebronchodilator forced expiratory volume in 1 second (FEV₁) over 52 weeks, rate of severe exacerbations, and rate of moderate, severe, or antibiotic-treated exacerbations. Additional assessments include spirometry, rescue medication use, the COPD assessment test, daily symptoms using the EXACT-Respiratory symptoms (E-RS) questionnaire, all-cause and COPD-related hospitalizations, and safety and pharmacokinetic measures.

Results: Across 17 countries, 2,354 participants were randomized from September 2011 to October 2014. Enrollment goal was met in October 2014, and study completion occurred in June 2016.

Conclusion: This study will further characterize the effects of roflumilast added to ICS/LABA on exacerbation rates, lung function, and health of severe–very severe COPD participants at risk of further exacerbations. The results will determine the clinical benefits of roflumilast combined with standard-of-care inhaled COPD treatment.

Keywords: exacerbation, RE²SPOND, phosphodiesterase-4, ICS/LABA, methodology, study design

Introduction

COPD is characterized by irreversible, progressive airflow limitation often associated with pulmonary inflammation.1–3 In a recent study, $32 billion USD were attributed to COPD-related medical costs, with a projected increase to $49 billion by 2020.4 Acute worsening of respiratory symptoms (exacerbations) contributes to morbidity and mortality in patients with COPD, is associated with chronic and acutely worsened airway inflammation,5 and further increases the cost of care.6 Patients with acute COPD
exacerbations have nearly double the all-cause quarterly incremental US health care costs than patients without exacerbations. They also have a greater prevalence of cardiovascular disease, gastroesophageal reflux, depression, and cognitive impairment.5,7 Roflumilast, an orally administered selective phosphodiesterase-4 inhibitor, increases the levels of intracellular 3′,5′-cyclic adenosine monophosphate in inflammatory cells and in the epithelial cells of the airways,1,2 which may contribute to the reduction of pulmonary inflammation.8

Roflumilast has been shown to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of COPD exacerbations.9–12 Studies have shown that combinations of roflumilast with long-acting β₂-agonists (LABAs) or long-acting muscarinic antagonists (LAMAs) are effective in reducing COPD exacerbations,10,13,14 and the Global Initiative for Obstructive Lung Disease recommends that roflumilast be prescribed in conjunction with one or more long-acting bronchodilators.3 Similar to inhaled corticosteroids (ICS), roflumilast may decrease inflammation,8,15 which may account for its ability to reduce the frequency of COPD exacerbations.10,13,16

Although studies evaluating the concomitant use of roflumilast with long-acting bronchodilators have generally excluded concomitant ICS treatment,10,13,14 a post hoc analysis of pooled data from two Phase III studies showed significant reductions in moderate to severe COPD exacerbation rates with roflumilast versus placebo in patients with severe, stable COPD who were receiving concurrent ICS (19% reduction; P < 0.01).11 Subsequent clinical trials that formed the basis for approval of roflumilast required subjects to discontinue concurrent ICS.10 Because roflumilast and ICS may reduce inflammation via different mechanisms, the combination of these drugs could have an additive or synergistic effect.17 Whether roflumilast added to an ICS/LABA combination would offer greater benefit for reducing COPD exacerbations and to what degree are important questions for clinicians managing patients who experience frequent COPD exacerbations. To address this need, a commitment was made at the time of roflumilast approval to pursue this question via two clinical trials. One was the recently completed Roflumilast and Exacerbations in participants receiving Appropriate Combination Therapy study (REACT), a randomized, controlled trial conducted in 21 countries (NCT01329029). In this study of 1,945 participants, the European formulation of roflumilast (film-coated tablets) reduced moderate to severe COPD exacerbations and hospitalizations when added to an ICS/LABA combination treatment in participants with severe COPD.18 The second study (RESPOND; NCT01443845) is evaluating the efficacy and safety of the US formulation of roflumilast (noncoated tablets) in a separate population of participants with severe COPD. A proportion of participants enrolled in RESPOND are allowed to use concomitant LAMA, which enables examination of the efficacy of roflumilast in reducing the rate of COPD exacerbations when added to ICS/LABA/LAMA triple therapy. The methodology, design, and study population of the ongoing RESPOND trial are described herein.

Methods Study design
In this multicenter, double-blind, placebo-controlled, parallel-group trial (NCT01443845), 2,354 participants were randomized 1:1 to receive once-daily roflumilast 500 μg or placebo, plus fixed-dose combination (FDC) ICS/LABA (fluticasone 250 μg/salmeterol 50 μg [one inhalation bid] or budesonide 160 μg/formoterol 4.5 μg [two inhalations bid]), for 52 weeks of double-blind treatment following a 2-week single-blind placebo run-in phase (Figure 1). Randomization was stratified by LAMA use. A safety follow-up conducted by telephone occurs either 4 weeks after the last visit of the double-blind treatment phase or following early termination. Participants who terminate the study early are followed to the scheduled Week 52 visit. The follow-up period includes one or two on-site visits (depending on the time of discontinuation) to perform vital sign and spirometry assessments and telephone contacts to collect information regarding COPD exacerbations, concomitant medication use, and adverse effects (AEs). This clinical study is conducted in accordance with the ethical principles of the Declaration of Helsinki and in compliance with the International Council for Harmonization Guidance on General Considerations for Clinical Trials and Good Clinical Practice. The study protocol was approved by the institutional review board at each study center in the United States and by the Independent Ethics Committee at each study center outside of the United States. All participants provided written informed consent prior to study participation. Although similar to the REACT trial, RESPOND has some notable differences in both design and conduct described in Table 1.

Study population
The planned enrollment is 2,300 males and females ≥40 years of age with a history of COPD for ≥12 months prior to screening associated with chronic productive cough for 3 months in each of 2 consecutive years (with other causes of productive cough excluded). Participants must have had two or more documented moderate or severe COPD exacerbations in the 12 months prior to screening. They are required to be using FDC ICS/LABA treatment for ≥3 months prior
to screening; participants must remain on the same COPD maintenance treatment between screening and randomization. Participants must have a postbronchodilator forced expiratory volume in 1 second (FEV₁) /forced vital capacity (FVC) ratio < 70% and postbronchodilator FEV₁ = 50% of predicted. Additionally, participants can be current or former smokers (smoking cessation ≥ 1 year prior to enrollment) with a smoking history of ≥ 20 pack-years.

Participants were excluded if, within the 4 weeks prior to enrollment, they had a moderate or severe COPD

---

**Table 1** Comparison of the REACT<sup>18,27</sup> and RE<sup>SPOND</sup> trials

<table>
<thead>
<tr>
<th></th>
<th>REACT</th>
<th>RE&lt;sup&gt;SPOND&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study design</td>
<td>Double-blind, placebo-controlled, parallel group, multicenter, Phase IV</td>
<td>Double-blind, placebo-controlled, parallel group, multicenter, Phase IV</td>
</tr>
<tr>
<td>Trial length</td>
<td>4-week single-blind run-in + 52-week DB treatment</td>
<td>2-week single-blind run-in + 52-week DB treatment</td>
</tr>
<tr>
<td>Number of participants</td>
<td>1,945</td>
<td>380 (expected)</td>
</tr>
<tr>
<td>Trial sites</td>
<td>203 sites across 21 countries</td>
<td>380 sites across 17 countries</td>
</tr>
<tr>
<td>Eligible participants</td>
<td>Diagnosis of severe to very severe COPD with chronic bronchitis and a history of COPD exacerbations</td>
<td>Diagnosis of severe to very severe COPD with chronic bronchitis and a history of COPD exacerbations</td>
</tr>
<tr>
<td>Randomization</td>
<td>1:1</td>
<td>1:1, stratified by LAMA use</td>
</tr>
<tr>
<td>Treatment</td>
<td>500 µg roflumilast or placebo + FDC ICS/LABA&lt;sup&gt;a&lt;/sup&gt; (+ 70% of participants were on LAMA&lt;sup&gt;a&lt;/sup&gt; treatment)</td>
<td>500 µg roflumilast or placebo + FDC ICS/LABA&lt;sup&gt;a&lt;/sup&gt; (+ up to 60% of participants allowed LAMA treatment)</td>
</tr>
<tr>
<td>Roflumilast formulation</td>
<td>Film-coated tablets (information on file)</td>
<td>Uncoated tablets</td>
</tr>
<tr>
<td>Allowed concomitant treatments</td>
<td>Salbutamol, corticosteroids, antibiotics&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Salbutamol/albuterol, corticosteroids, H1-antihistamines, antibiotics, SAMA&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Follow-up</td>
<td>4 weeks (safety) and 12 weeks</td>
<td>4 weeks (safety) or up to the scheduled Week 52 visit for early terminated participants</td>
</tr>
<tr>
<td>Primary outcome</td>
<td>Rate of moderate or severe COPD exacerbations per participant per year&lt;sup&gt;c&lt;/sup&gt;</td>
<td>Rate of moderate or severe COPD exacerbations per participant per year&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>Primary outcome analyses</td>
<td>Poisson regression model with overdispersion correction and negative binomial regression model</td>
<td>Negative binomial regression model and sensitivity analysis</td>
</tr>
<tr>
<td>Secondary outcomes</td>
<td>Change in postbronchodilator FEV₁, rate of severe COPD exacerbations, rate of moderate to severe or antibiotic-treated COPD exacerbations, spirometry</td>
<td>Change in prebronchodilator FEV₁, rate of severe COPD exacerbations; and rate of moderate, severe, or antibiotic-treated exacerbations</td>
</tr>
<tr>
<td>Additional/safety outcomes</td>
<td>Electronic rescue medication diary, CAT, major adverse cardiac events, mortality</td>
<td>Spirometry, electronic rescue medication diary, CAT, EXACT-PRO, major adverse cardiac events, C-SSRS</td>
</tr>
<tr>
<td>Pharmacokinetics</td>
<td>Sparse sampling (n=986)</td>
<td>Sparse sampling (n=420), serial sampling (n=40)</td>
</tr>
</tbody>
</table>

**Notes:**
- Participants were allowed to use any commercially available fixed ICS/LABA combination at the maximum dosage approved in each country (not sponsored).
- Participants were classified as receiving concomitant treatment with a LAMA if they used this therapy during baseline and at least 80% of the duration of the treatment period.
- Sponsor provided fluticasone 250 µg/salmeterol 50 µg (one inhalation twice daily) or budesonide 160 µg/formoterol 4.5 µg (two inhalations twice daily). For treatment of purulent sputum or suspected bacterial infection. If not on a LAMA. Moderate COPD exacerbations are defined as those requiring corticosteroid treatment; severe COPD exacerbations are those that require hospitalization and/or lead to death.

**Abbreviations:**
- CAT, COPD assessment test; C-SSRS, Columbia Suicide Severity Rating Scale; DB, double-blind; EXACT-PRO, exacerbation of chronic pulmonary disease tool – patient reported outcomes; FDC, fixed-dose combination; FEV₁, forced expiratory volume in 1 second; ICS, inhaled corticosteroid; LABA, long-acting β<sub>2</sub>-agonist; LAMA, long-acting muscarinic antagonist; REACT, Roflumilast and Exacerbations in patients receiving Appropriate Combination Therapy; SAMA, short-acting muscarinic antagonist.
exacerbation and/or COPD exacerbation treated with antibiotics or systemic corticosteroids or a lower respiratory tract infection. Other exclusionary criteria include diagnoses of other lung diseases, moderate-to-severe liver impairment (Child-Pugh B or C), HIV or hepatitis infection, current diagnosis of asthma, cancer in the past 5 years, α1-antitrypsin deficiency, a clinically significant cardiovascular condition, a resting QTc interval >470 ms, or a body mass index ≥45 kg/m². Participants must not have used theophylline or add-on theophylline derivatives 2 weeks prior to screening or have any clinically relevant abnormalities in clinical laboratory tests. Participants must not have participated in an acute pulmonary rehabilitation program in the previous 3 months (except if on a stable pulmonary rehabilitation exercise regimen for ≥6 weeks).

**Concomitant medications**

In addition to background FDC ICS/LABA treatment as part of the study treatment, up to 60% of enrolled participants are permitted to use a LAMA (eg, tiotropium) if treatment is stable (taking the drug for ≥3 months prior to screening with no change in dose). For participants not using a LAMA, treatment with a short-acting muscarinic antagonist (eg, ipratropium and oxtropium) is allowed. Corticosteroids (oral, parenteral, and intranasal) or H1-antihistamines (eg, loratadine) are also permitted as needed, and sponsor-provided albuterol/salbutamol (rescue medication) is supplied as needed.

**Outcome and safety measures**

As the objective of this study is to determine whether roflumilast added to an ICS/LABA combination could offer greater benefit for reducing COPD exacerbations, the primary efficacy measure for this study is the rate of moderate or severe COPD exacerbations per participant per year. Moderate COPD exacerbations are defined as those requiring corticosteroid treatment; severe COPD exacerbations are those that require hospitalization and/or those that lead to death. Secondary efficacy outcomes include mean change in prebronchodilator FEV₁ from randomization to Week 52 of double-blind treatment, the rate of severe COPD exacerbations, and the rate of moderate, severe, or antibiotic-treated COPD exacerbations. Additional efficacy assessments include spirometry (FVC, FEV₁/FVC ratio, and forced expiratory volume in the first 6 seconds [FEV₆]), rescue medication use, the COPD Assessment Test, daily symptoms as measured by the EXAcerbation of Chronic Pulmonary Disease Tool – Patient Reported Outcomes (EXACT-PRO) tool, and all-cause and COPD-related hospitalizations.

Safety assessments include AE reporting, vital signs, physical examinations, body weight, electrocardiograms, clinical laboratory measures, major adverse cardiac events, and the Columbia Suicide Severity Rating Scale (C-SSRS). Any AE not present before the first dose of study drug that occurred during the double-blind phase or increased in severity during treatment with the investigational product is classified as a treatment-emergent AE.

**Pharmacokinetics**

For serial pharmacokinetic (PK) analyses, blood samples will be taken from 40 participants at several study sites to determine roflumilast and roflumilast N-oxide plasma concentration–time profiles. Samples will be collected on Visit 7 at the following time points: predose (0 hour) and 0.25 hour, 0.5 hour, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, and 24 hours postdose. For sparse population PK analyses, predose blood samples will be collected from ~20% of the total study population (n=420) on Visits 5, 7, and 8.

**Statistical analyses**

Efficacy analyses will be performed on the intention-to-treat (ITT) population, consisting of all randomized participants who received one or more dose of double-blind study drug and based on the treatment to which they were randomized. Safety analyses will be analyzed for the safety population, consisting of all randomized participants who received one or more dose of study drug and based on the treatment received. Demographic and other baseline characteristics will be summarized by treatment and pooled across treatment groups for the safety and ITT populations. The primary outcome will be analyzed using a negative binomial regression model with number of COPD exacerbations as a dependent variable, treatment and stratum (LAMA or no LAMA) as independent variables, and logarithm of exposure time (in years) as an offset. Change in prebronchodilator FEV₁, and other spirometry measures will be assessed via repeated measurement models, with the dependent variable being change from randomization at each scheduled postrandomization visit, and treatment, stratum (LAMA or no LAMA), baseline, time, treatment by time and baseline by time interactions as independent variables. All statistical tests will be two sided and performed at the 5% significance level for the main effects; confidence intervals will be two sided with 95% confidence. Based on assumptions of a mean of 1.35 COPD exacerbations per participant per year in the placebo group and a mean exposure time of 287 days across both treatment arms, a sample size of 2,300 randomized participants has ≥90%
power to detect an 18% reduction in COPD exacerbation rates with roflumilast treatment versus placebo.

Additionally, a sensitivity analysis will be performed to determine whether missing data from participants after premature treatment discontinuation have an effect on the primary outcome measure (moderate–severe exacerbation rates). A negative binomial regression will be applied on the pre- and postdiscontinuation data (collected from follow-up calls and visits). Exposure time will be recalculated only for early-terminating participants based on the last data collected. A second analysis will be performed to examine the potential effect of participants in the no LAMA stratum who initiate LAMA after study randomization. Exacerbation data collected after these participants begin LAMA use will not be analyzed, and exposure calculations will only include the number of days of pre-LAMA treatment.

All safety data will be summarized, and no formal hypothesis tests will be used. The serial PK parameters of peak plasma concentration ($C_{\text{max}}$), area under the curve, time to peak plasma concentration ($T_{\text{max}}$), and half-life ($T_{1/2}$) will be calculated and summarized. Sparse PK and serial PK data will be added to an existing roflumilast population PK model combining data from several studies.

Results

Across 17 countries, 2,354 participants were randomized between September 2011 and October 2014. The study enrollment goal was met in October 2014 (Figure 2), and study completion occurred in June 2016. Demographics of the study population are described in Table 2.
Table 2 Baseline demographics and characteristics (safety population)

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Total (N=2,352)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD), years</td>
<td>64.5 (8.6)</td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>1,615 (68.7)</td>
</tr>
<tr>
<td>White, n (%)</td>
<td>1,879 (79.9)</td>
</tr>
<tr>
<td>Weight, mean (SD), kg</td>
<td>73.1 (19.1)</td>
</tr>
<tr>
<td>BMI, mean (SD), kg/m²</td>
<td>25.9 (5.8)</td>
</tr>
<tr>
<td>Current smoker, n (%)</td>
<td>926 (39.4)</td>
</tr>
<tr>
<td>Years smoking, mean (SD)</td>
<td>40.7 (10.5)*</td>
</tr>
<tr>
<td>COPD severity, n (%)</td>
<td></td>
</tr>
<tr>
<td>Moderate</td>
<td>1 (&lt;1)</td>
</tr>
<tr>
<td>Severe</td>
<td>1,417 (62.2)</td>
</tr>
<tr>
<td>Very severe</td>
<td>920 (39.1)</td>
</tr>
<tr>
<td>Prebronchodilator FEV₁, % predicted, mean (SD), %</td>
<td>29.9 (8.9)*</td>
</tr>
<tr>
<td>Number of COPD exacerbations in 12 months prior to screening, n (%)</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>23 (1.0)</td>
</tr>
<tr>
<td>2–5</td>
<td>2,290 (97.4)</td>
</tr>
<tr>
<td>6+</td>
<td>39 (1.7)</td>
</tr>
<tr>
<td>Stable LAMA use, n (%)</td>
<td>1,094 (46.5)</td>
</tr>
<tr>
<td>Suicidal ideation or behavior, n (%)</td>
<td>195 (8.3)*</td>
</tr>
</tbody>
</table>

Notes: N=2,349. Abbreviations: BMI, body mass index; FEV₁, forced expiratory volume in 1 second; LAMA, long-acting muscarinic antagonist; SD, standard deviation.

hospital admissions by 24% in participants with severe COPD. Similar to the REACT trial, participants in the RE²SPOND study must remain on ICS/LABA treatment throughout the study. The RE²SPOND protocol limits concurrent LAMA use to 60% of participants to ensure robust analyses of the effects of roflumilast when administered with concurrent ICS/LABA or triple therapy. In the REACT study, 70% of enrolled participants were on concurrent LAMA as no such restrictions on LAMA use were imposed. Notably, significant reductions in exacerbation rates were observed in participants using roflumilast added to ICS/LABA treatment, regardless of concomitant LAMA use. In the RE²SPOND trial, 47% of enrolled participants were on ICS/LABA/LAMA triple therapy at baseline, which should provide the opportunity to assess any potential additive effects of roflumilast with concurrent dual or triple therapy in distinct patient populations. If the results of this study confirm that these combinations are safe and effective in decreasing COPD exacerbation rates, this would present strong evidence supporting roflumilast as an added option for patients who continue to experience COPD exacerbations while on ICS/LABA or ICS/LABA/LAMA.

RE²SPOND will also allow us to address additional questions of clinical relevance. As the roflumilast knowledge base grows, it will be possible to determine whether there are beneficial effects or AEs in specific groups of COPD participants, such as those with common comorbidities such as diabetes and heart disease. Compared with the REACT study, the RE²SPOND study had slightly fewer males (68.7% vs 74.6%), current smokers (39.4% vs 43.6%), and a higher percentage of patients with very severe COPD (39.3% vs 29.1%). However, both studies share similar methodologies and generally similar baseline patient characteristics, potentially allowing these data sets to be pooled for more robust analyses.

Roflumilast was approved based on data that demonstrated its efficacy and acceptable safety profile, but questions remained about its role when added to other therapies, especially ICS/LABA combinations. Results from RE²SPOND, a study conducted as part of a postmarketing commitment, will address this gap and provide important information to help guide clinical practice.

Conclusion
This Phase IV study will further characterize the effects of roflumilast in combination with common ICS/LABA fixed-dose drugs on COPD exacerbation rates, lung function, and health status of patients with severe–very severe COPD who are at risk of further COPD exacerbations. Results from this study will be vital in determining the clinical benefits of the US formulation of roflumilast (uncoated tablet) when combined with standard-of-care inhaled COPD treatments.

Acknowledgments
The authors thank Kristen Andersen, PhD, and Lynn Anderson, PhD, of Prescott Medical Communications Group, Chicago, IL, USA, for medical writing support funded by AstraZeneca LP (Wilmington, DE, USA). This information was previously presented in poster format at the 2015 American Thoracic Society Annual Meeting, May 15–20, 2015, Denver, CO, USA. This study was supported by Forest Laboratories LLC, an affiliate of Actavis, Inc (Parsippany, NJ, USA) and AstraZeneca LP (Wilmington, DE, USA).

Author contributions
All authors provided substantial contributions to the convention or design of the work, acquisition, analysis, or interpretation of data for the work. All authors drafted the work or revised it critically for important intellectual content. All authors provided final approval of the version to be published and have agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Disclosure
SI Rennard has received personal fees from the American Board of Internal Medicine, Able Associates, Advantage...
Healthcare, Align2Action, Almirall, Association of Polysonography Technologist, American Thoracic Society, AstraZeneca, Baxter, Boehringer-Ingelheim, Chiesi, CIPLA, ClearView Healthcare, Cleveland Clinic, CME Incite, Complete Medical Group, COPDFoundation, Cory Paeth, CSA, CSL., California Thoracic Society Carmel, Daiichi Sankyo, Decision Resources, Dunn Group, Easton Associates, Elevation Pharma, FirstWord, Forest, Frankel Group, Gerson, GlaxoSmithKline, Gilead, Grifols, GroupH, Guidepoint Global, Haymarket, HealthStar, Huron Consulting, Incite, Inthought, IntraMed (Forest), Johnson & Johnson, LEK, McKinsey, Medical Knowledge, MedImmune, Methodist Health System (Dallas), Navigant, NCI Consulting, Novartis, Nuvis, Pearl, Penn Technology, Pfizer, PlanningShop, Prescott, Pro Ed Comm, ProiMed, PSL FirstWord, Pulmatrix, Quadrant, Qessential, Regeneron, Saatchi and Saatchi, Schlesinger Associates, Strategic North, Synapse, Takeda, Theron, and WebMD. He also received grant support from the National Heart, Lung, and Blood Institute, the Nebraska Department of Health and Human Services, Otsuka, Pfizer, GlaxoSmithKline, Boehringer-Ingelheim, Nycomed, AstraZeneca, Centocor, and Almirall and is an employee of AstraZeneca. FJ Martinez has received personal fees from Forest, Janssen, GlaxoSmithKline, Nycomed/ Takeda, Amgen, AstraZeneca, Boehringer-Ingelheim, Carden Jennings, CSA Medical, Ikaria/Bellerophon, Genentech, Merck, Novartis, Pfizer, Roche, Sunovion, Theravance, Axon Communication, CME Incite, California Society for Allergy and Immunology, Annenberg, Inova Health System, Integritas, InThought, Miller Medical, National Association for Continuing Education, Paradigm, PeerVoice, UpToDate, Haymarket Communications, St John’s Hospital, St Mary’s Hospital, Western Society of Allergy and Immunology, Informa, Bioscale, Unity Biotechnology, Kadmon, Vertex, American Thoracic Society, Academic CME, Falco, MedScape, Genzyme, Johnson & Johnson, University of Texas Southwestern, and Spectrum Health System. He also received nonfinancial support from Boehringer-Ingelheim, Centocor, Gilead, Promedior, Roche/ Genentech, Bayer, Veracyte, and Biogen and a grant from the National Institutes of Health. KF Rabe received a grant from the German Federal Ministry of Education and Research, Novartis, and Boehringer-Ingelheim. He has also received personal fees from AstraZeneca, Boehringer-Ingelheim, Chiesi Pharmaceutical, Novartis, Takeda, and Intermune. S Sethi has received personal fees from AstraZeneca, Boehringer-Ingelheim, Forest, GlaxoSmithKline, Novartis, Pfizer, and Sunovion. He also received grant support from AstraZeneca, GlaxoSmithKline, Pearl, and Dey E Pizzichini has nothing to disclose. A McVor has received personal fees for honoraria CME from AstraZeneca, Novartis, Merck, and Boehringer-Ingelheim. S Siddiqui is an employee of AstraZeneca. A Anzueto has received a grant from GlaxoSmithKline and consultant fees from GlaxoSmithKline, AstraZeneca, Novartis, and Boehringer-Ingelheim. H Zhu is an employee of Allergan. The authors report no other conflicts of interest in this work.

References

11. Rennard SI, Calverley PM, Goehring UM, Bredenbroker D, Martinez FJ. Reduction of exacerbations by the PDE4 inhibitor roflumilast – the importance of defining different subsets of patients with COPD. Respir Res. 2011;12:18.


